Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease

World Journal of Gastroenterology

Volumn 20, Issue 7, 2014, Pages 1724-1745

  Ballestri, Stefano ^a,b   Lonardo, Amedeo ^b   Bonapace, Stefano ^c   Byrne, Christopher D ^d   Loria, Paola ^b   Targher, Giovanni ^e  

^a Pavullo Hospital   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^d UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Arrhythmias; Arrhythmic complications; Cardiac complications; Cardiovascular disease; Coronary heart disease; Myocardial dysfunction; Non alcoholic fatty liver disease; Valvular heart disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; COLECALCIFEROL; EXENDIN 4; EZETIMIBE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN SENSITIZING AGENT; INTERLEUKIN 6; LIRAGLUTIDE; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA; INSULIN;

ALCOHOL CONSUMPTION; ARTERIOSCLEROSIS; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; ECHOCARDIOGRAPHY; HEART ARRHYTHMIA; HEART DISEASE; HEART INFARCTION; HEART MUSCLE METABOLISM; HEART VENTRICLE ARRHYTHMIA; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; SLEEP DISORDERED BREATHING; SYSTEMATIC REVIEW (TOPIC); WEIGHT REDUCTION; ARRHYTHMIAS, CARDIAC; CARDIOVASCULAR DISEASE; CHEMISTRY; COMORBIDITY; COMPLICATION; CORONARY DISEASE; FATTY LIVER; HEART ATRIUM FIBRILLATION; HEART MUSCLE; LIFESTYLE; LIVER; METABOLISM; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PREVALENCE; RISK FACTOR;

ARRHYTHMIAS, CARDIAC; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; COMORBIDITY; CORONARY DISEASE; FATTY LIVER; HUMANS; INSULIN; LIFE STYLE; LIVER; MYOCARDIUM; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; RESEARCH DESIGN; RISK FACTORS;

EID: 84894234723     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i7.1724     Document Type: Article

References (180)

1. Diabetes mellitus; auricular fibrillation; arteriosclerosis obliterans of the legs; gangrene of the 1st and 2d toes of the right foot; fatty degeneration of the liver. Arq Bras Med 1952; 42: 212-216 [PMID: 14953851]
2. Lonardo A, Bellini M, Tondelli E, Frazzoni M, Grisendi A, Pulvirenti M, Della Casa G. Nonalcoholic steatohepatitis and the "bright liver syndrome": should a recently expanded clinical entity be further expanded? Am J Gastroenterol 1995; 90: 2072-2074 [PMID: 7485040]
3. Targher G, Bertolini L, Padovani R, Zenari L, Zoppini G, Falezza G. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care 2004; 27: 2498-2500 [PMID: 15451925. DOI: 10.2337/diacare.27.10.2498]
4. Lonardo A, Lombardini S, Scaglioni F, Ballestri S, Verrone AM, Bertolotti M, Carulli L, Ganazzi D, Carulli N, Loria P. Fatty liver, carotid disease and gallstones: a study of agerelated associations. World J Gastroenterol 2006; 12: 5826-5833 [PMID: 17007049]
5. Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 2008; 49: 600-607 [PMID: 18672311 DOI: 10.1016/j.jhep.2008.06.012]
6. Holt LJ, Krutchinsky AN, Morgan DO. Positive feedback sharpens the anaphase switch. Nature 2008; 454: 353-357 [PMID: 18552837 DOI: 10.1016/j.jhep.2008.05.024]
7. Perseghin G, Lattuada G, De Cobelli F, Esposito A, Belloni E, Ntali G, Ragogna F, Canu T, Scifo P, Del Maschio A, Luzi L. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 2008; 47: 51-58 [PMID: 17955548 DOI: 10.1002/hep.21983]
8. Bonapace S, Perseghin G, Molon G, Canali G, Bertolini L, Zoppini G, Barbieri E, Targher G. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care 2012; 35: 389-395 [PMID: 22210573 DOI: 10.2337/dc11-1820]
9. Targher G, Mantovani A, Pichiri I, Rigolon R, Dauriz M, Zoppini G, Morani G, Vassanelli C, Bonora E. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. Clin Sci (Lond) 2013; 125: 301-309 [PMID: 23596966 DOI: 10.1042/CS20130036]
10. Targher G, Valbusa F, Bonapace S, Bertolini L, Zenari L, Rodella S, Zoppini G, Mantovani W, Barbieri E, Byrne CD. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS One 2013; 8: e57183 [PMID: 23451184 DOI: 10.1371/journal.pone.0057183]
11. Musso G, Gambino R, Cassader M, Pagano G. Metaanalysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-649 [PMID: 21039302. DOI: 10.3109/07853890.2010.518623]
12. Maurantonio M, Ballestri S, Odoardi MR, Lonardo A, Loria P. Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk? Arch Med Res 2011; 42: 337-353 [PMID: 21843565 DOI: 10.1016/j.arcmed.2011.08.004]
13. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 2012; 33: 1190-1200 [PMID: 22408036 DOI: 10.1093/eurheartj/ehr453]
14. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-1350 [PMID: 20879883 DOI: 10.1056/ NEJMra0912063]
15. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10: 330-344 [PMID: 23507799 DOI: 10.1038/nrgastro.2013.41]
16. Targher G, Byrne CD. Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab 2013; 98: 483-495 [PMID: 23293330 DOI: 10.1210/jc.2012-3093]
17. Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, Zoli M, Marchesini G. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005; 42: 473-480 [PMID: 15981216 DOI: 10.1002/hep.20781]
18. Salvi P, Ruffini R, Agnoletti D, Magnani E, Pagliarani G, Comandini G, Praticò A, Borghi C, Benetos A, Pazzi P. Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. J Hypertens 2010; 28: 1699-1707 [PMID: 20467324 DOI: 10.1097/HJH.0b013e32833a7de6]
19. Pacifico L, Anania C, Martino F, Cantisani V, Pascone R, Marcantonio A, Chiesa C. Functional and morphological vascular changes in pediatric nonalcoholic fatty liver disease. Hepatology 2010; 52: 1643-1651 [PMID: 20890890 DOI: 10.1002/hep.23890]
20. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Zenari L, Cigolini M, Falezza G, Arcaro G. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006; 29: 1325-1330 [PMID: 16732016 DOI: 10.2337/ dc06-0135]
21. Colak Y, Senates E, Yesil A, Yilmaz Y, Ozturk O, Doganay L, Coskunpinar E, Kahraman OT, Mesci B, Ulasoglu C, Tuncer I. Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine 2013; 43: 100-107 [PMID: 22661277. DOI: 10.1007/s12020-012-9712-1]
22. Abdulla J, Asferg C, Kofoed KF. Prognostic value of absence or presence of coronary artery disease determined by 64-slice computed tomography coronary angiography a systematic review and meta-analysis. Int J Cardiovasc Imaging 2011; 27: 413-420 [PMID: 20549366 DOI: 10.1007/s10554-010-9652-x]
23. Chen CH, Nien CK, Yang CC, Yeh YH. Association between nonalcoholic fatty liver disease and coronary artery calcification. Dig Dis Sci 2010; 55: 1752-1760 [PMID: 19688595 DOI: 10.1007/s10620-009-0935-9]
24. Jung DH, Lee YJ, Ahn HY, Shim JY, Lee HR. Relationship of hepatic steatosis and alanine aminotransferase with coronary calcification. Clin Chem Lab Med 2010; 48: 1829-1834 [PMID: 20961204 DOI: 10.1515/CCLM.2010.349]
25. Sung KC, Wild SH, Kwag HJ, Byrne CD. Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10,153 people. Diabetes Care 2012; 35: 2359-2364 [PMID: 22829522 DOI: 10.2337/ dc12-0515]
26. Kim D, Choi SY, Park EH, Lee W, Kang JH, Kim W, Kim YJ, Yoon JH, Jeong SH, Lee DH, Lee HS, Larson J, Therneau TM, Kim WR. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 2012; 56: 605-613 [PMID: 22271511 DOI: 10.1002/hep.25593]
27. Liu J, Musani SK, Bidulescu A, Carr JJ, Wilson JG, Taylor HA, Fox CS. Fatty liver, abdominal adipose tissue and atherosclerotic calcification in African Americans: the Jackson Heart Study. Atherosclerosis 2012; 224: 521-525 [PMID: 22902209. DOI: 10.1016/j.atherosclerosis.2012.07.042]
28. Lautamäki R, Borra R, Iozzo P, Komu M, Lehtimäki T, Salmi M, Jalkanen S, Airaksinen KE, Knuuti J, Parkkola R, Nuutila P. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 2006; 291: E282-E290 [PMID: 16478772 DOI: 10.1152/ajpendo.00604.2005]
29. Yilmaz Y, Kurt R, Yonal O, Polat N, Celikel CA, Gurdal A, Oflaz H, Ozdogan O, Imeryuz N, Kalayci C, Avsar E. Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: association with liver fibrosis. Atherosclerosis 2010; 211: 182-186 [PMID: 20181335 DOI: 10.1016/j.athe rosclerosis.2010.01.049]
30. Nakamori S, Onishi K, Nakajima H, Yoon YE, Nagata M, Kurita T, Yamada T, Kitagawa K, Dohi K, Nakamura M, Sakuma H, Ito M. Impaired myocardial perfusion reserve in patients with fatty liver disease assessed by quantitative myocardial perfusion magnetic resonance imaging. Circ J 2012; 76: 2234-2240 [PMID: 22664721 DOI: 10.1253/circj. CJ-11-1487]
31. Lin YC, Lo HM, Chen JD. Sonographic fatty liver, overweight and ischemic heart disease. World J Gastroenterol 2005; 11: 4838-4842 [PMID: 16097054]
32. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30: 1212-1218 [PMID: 17277038 DOI: 10.2337/dc06-2247]
33. Arslan U, Türkoǧlu S, Balcioǧlu S, Tavil Y, Karakan T, Cengel A. Association between nonalcoholic fatty liver disease and coronary artery disease. Coron Artery Dis 2007; 18: 433-436 [PMID: 17700213 DOI: 10.1097/MCA.0b013e3282583c0d]
34. Mirbagheri SA, Rashidi A, Abdi S, Saedi D, Abouzari M. Liver: an alarm for the heart? Liver Int 2007; 27: 891-894 [PMID: 17696926 DOI: 10.1111/j.1478-3231.2007.01531.x]
35. Alper AT, Hasdemir H, Sahin S, Ontürk E, Akyol A, Nurkalem Z, Cakmak N, Erdinler I, Gürkan K. The relationship between nonalcoholic fatty liver disease and the severity of coronary artery disease in patients with metabolic syndrome. Turk Kardiyol Dern Ars 2008; 36: 376-381 [PMID: 19155640]
36. Akabame S, Hamaguchi M, Tomiyasu K, Tanaka M, Kobayashi-Takenaka Y, Nakano K, Oda Y, Yoshikawa T. Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT). Circ J 2008; 72: 618-625 [PMID: 18362435. DOI: 10.1253/circj.72.618]
37. Açikel M, Sunay S, Koplay M, Gündoǧdu F, Karakelleoǧlu S. Evaluation of ultrasonographic fatty liver and severity of coronary atherosclerosis, and obesity in patients undergoing coronary angiography. Anadolu Kardiyol Derg 2009; 9: 273-279 [PMID: 19666428]
38. Assy N, Djibre A, Farah R, Grosovski M, Marmor A. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology 2010; 254: 393-400 [PMID: 20093511 DOI: 10.1148/radiol.09090769]
39. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Pichiri I, Sorgato C, Zenari L, Bonora E. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol 2010; 53: 713-718 [PMID: 20619918 DOI: 10.1016/ j.jhep.2010.04.030]
40. Sun L, Lü SZ. Association between non-alcoholic fatty liver disease and coronary artery disease severity. Chin Med J (Engl) 2011; 124: 867-872 [PMID: 21518594 DOI: 10.3760/ cma.j.issn.0366-6999.2011.06.012]
41. Wong VW, Wong GL, Yip GW, Lo AO, Limquiaco J, Chu WC, Chim AM, Yu CM, Yu J, Chan FK, Sung JJ, Chan HL. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 2011; 60: 1721-1727 [PMID: 21602530 DOI: 10.1136/gut.2011.242016]
42. Domanski JP, Park SJ, Harrison SA. Cardiovascular disease and nonalcoholic fatty liver disease: does histologic severity matter? J Clin Gastroenterol 2012; 46: 427-430 [PMID: 22469639. DOI: 10.1097/MCG.0b013e31822fb3f7]
43. Agaç MT, Korkmaz L, Cavusoglu G, Karadeniz AG, Agaç S, Bektas H, Erkan H, Varol MO, Vatan MB, Acar Z, Mentese U, Celik S. Association between nonalcoholic fatty liver disease and coronary artery disease complexity in patients with acute coronary syndrome: a pilot study. Angiology 2013; 64: 604-608 [PMID: 23439214 DOI: 10.1177/0003319713479155]
44. Boddi M, Tarquini R, Chiostri M, Marra F, Valente S, Giglioli C, Gensini GF, Abbate R. Nonalcoholic fatty liver in nondiabetic patients with acute coronary syndromes. Eur J Clin Invest 2013; 43: 429-438 [PMID: 23480577 DOI: 10.1111/ eci.12065]
45. Inci MF, Özkan F, Ark B, Vurdem ÜE, Ege MR, Sincer I, Zorlu A. Sonographic evaluation for predicting the presence and severity of coronary artery disease. Ultrasound Q 2013; 29: 125-130 [PMID: 23609339 DOI: 10.1097/ RUQ.0b013e318291580e]
46. Arslan U, Kocaoǧlu I, Balci{dotless} M, Duyuler S, Korkmaz A. The association between impaired collateral circulation and nonalcoholic fatty liver in patients with severe coronary artery disease. J Cardiol 2012; 60: 210-214 [PMID: 22738690 DOI: 10.1016/j.jjcc.2012.05.003]
47. Fraser A, Harris R, Sattar N, Ebrahim S, Smith GD, Lawlor DA. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol 2007; 27: 2729-2735 [PMID: 17932318 DOI: 10.1161/ATVBAHA.107.152298]
48. Schindhelm RK, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD, Heine RJ, Diamant M. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007; 191: 391-396 [PMID: 16682043. DOI: 10.1016/j.atherosclerosis.2006.04.006]
49. Goessling W, Massaro JM, Vasan RS, D'Agostino RB, Ellison RC, Fox CS. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 2008; 135: 1935-144, 1944. e1 [PMID: 19010326. DOI: 10.1053/j.gastro.2008.09.018]
50. Dunn W, Xu R, Wingard DL, Rogers C, Angulo P, Younossi ZM, Schwimmer JB. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 2008; 103: 2263-2271 [PMID: 18684196 DOI: 10.1111/j.1572-0241.2008.02034.x]
51. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008; 49: 608-612 [PMID: 18682312 DOI: 10.1016/j.jhep.2008.06.018]
52. Ruhl CE, Everhart JE. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology 2009; 136: 477-85. e11 [PMID: 19100265 DOI: 10.1053/j.gastro.2008.10.052]
53. Yun KE, Shin CY, Yoon YS, Park HS. Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans. Atherosclerosis 2009; 205: 533-537 [PMID: 19159884 DOI: 10.1016/j.atherosclerosis.200 8.12.012]
54. Calori G, Lattuada G, Ragogna F, Garancini MP, Crosignani P, Villa M, Bosi E, Ruotolo G, Piemonti L, Perseghin G. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology 2011; 54: 145-152 [PMID: 21488080. DOI: 10.1002/hep.24356]
55. Lerchbaum E, Pilz S, Grammer TB, Boehm BO, Stojakovic T, Obermayer-Pietsch B, März W. The fatty liver index is associated with increased mortality in subjects referred to coronary angiography. Nutr Metab Cardiovasc Dis 2013; 23: 1231-1238 [PMID: 23557879 DOI: 10.1016/ j.numecd.2013.02.004]
56. Jepsen P, Vilstrup H, Mellemkjaer L, Thulstrup AM, Olsen JH, Baron JA, Sørensen HT. Prognosis of patients with a diagnosis of fatty liver--a registry-based cohort study. Hepatogastroenterology 2003; 50: 2101-2104 [PMID: 14696473]
57. Targher G, Bertolini L, Rodella S, Tessari R, Zenari L, Lippi G, Arcaro G. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007; 30: 2119-2121 [PMID: 17519430 DOI: 10.2337/dc07-0349]
58. Soler Rodriguez F, Miguez Santiyan MP, Pedrera Zamorano JD, Roncero Cordero V. An outbreak of lupinosis in sheep. Vet Hum Toxicol 1991; 33: 492-494 [PMID: 1746145]
59. Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E, Clark JM. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011; 343: d6891 [PMID: 22102439 DOI: 10.1136/bmj.d6891]
60. Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 2012; 10: 646-650 [PMID: 22245962 DOI: 10.1016/ j.cgh.2011.12.039]
61. Zhou YJ, Li YY, Nie YQ, Huang CM, Cao CY. Natural course of nonalcoholic fatty liver disease in southern China: a prospective cohort study. J Dig Dis 2012; 13: 153-160 [PMID: 22356310. DOI: 10.1111/j.1751-2980.2011.00571.x]
62. Younossi ZM, Otgonsuren M, Venkatesan C, Mishra A. In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism 2013; 62: 352-360 [PMID: 22999011 DOI: 10.1016/ j.metabol.2012.08.005]
63. Haring R, Wallaschofski H, Nauck M, Dörr M, Baumeister SE, Völzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology 2009; 50: 1403-1411 [PMID: 19670414 DOI: 10.1002/hep.23135]
64. Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57: 1357-1365 [PMID: 23175136 DOI: 10.1002/hep.26156]
65. Treeprasertsuk S, Leverage S, Adams LA, Lindor KD, St Sauver J, Angulo P. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int 2012; 32: 945-950 [PMID: 22299674 DOI: 10.1111/ j.1478-3231.2011.02753.x]
66. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419 [PMID: 10348825]
67. Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sørensen TI, Becker U, Bendtsen F. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004; 53: 750-755 [PMID: 15082596 DOI: 10.1136/ gut.2003.019984]
68. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121 [PMID: 16012941]
69. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term followup of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873 [PMID: 17006923 DOI: 10.1002/ hep.21327]
70. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, Younossi ZM. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7: 234-238 [PMID: 19049831 DOI: 10.1016/j.cgh.2008.11.005]
71. Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51: 595-602 [PMID: 20014114 DOI: 10.1002/ hep.23314]
72. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33 [PMID: 17081293 DOI: 10.1186/1471-230X-6-33]
73. Jiang ZY, Xu CY, Chang XX, Li WW, Sun LY, Yang XB, Yu LF. Fatty liver index correlates with non-alcoholic fatty liver disease, but not with newly diagnosed coronary artery atherosclerotic disease in Chinese patients. BMC Gastroenterol 2013; 13: 110 [PMID: 23834773 DOI: 10.1186/1471-230X-13-110]
74. Rijzewijk LJ, van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, Romijn JA, de Roos A, Lamb HJ. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 2008; 52: 1793-1799 [PMID: 19022158 DOI: 10.1016/j.jacc.2008.07.062]
75. Rijzewijk LJ, Jonker JT, van der Meer RW, Lubberink M, de Jong HW, Romijn JA, Bax JJ, de Roos A, Heine RJ, Twisk JW, Windhorst AD, Lammertsma AA, Smit JW, Diamant M, Lamb HJ. Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes. J Am Coll Cardiol 2010; 56: 225-233 [PMID: 20620743 DOI: 10.1016/j.jacc.2010.02.049]
76. Goland S, Shimoni S, Zornitzki T, Knobler H, Azoulai O, Lutaty G, Melzer E, Orr A, Caspi A, Malnick S. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol 2006; 40: 949-955 [PMID: 17063117. DOI: 10.1097/01.mcg.0000225668.53673.e6]
77. Fallo F, Dalla Pozza A, Sonino N, Lupia M, Tona F, Federspil G, Ermani M, Catena C, Soardo G, Di Piazza L, Bernardi S, Bertolotto M, Pinamonti B, Fabris B, Sechi LA. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr Metab Cardiovasc Dis 2009; 19: 646-653 [PMID: 19278843 DOI: 10.1016/j.numecd.2008.12.007]
78. Fotbolcu H, Yakar T, Duman D, Karaahmet T, Tigen K, Cevik C, Kurtoglu U, Dindar I. Impairment of the left ventricular systolic and diastolic function in patients with nonalcoholic fatty liver disease. Cardiol J 2010; 17: 457-463 [PMID: 20865675]
79. Mantovani A, Zoppini G, Targher G, Golia G, Bonora E. Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive Type 2 diabetic individuals. J Endocrinol Invest 2012; 35: 215-218 [PMID: 22490991]
80. Hallsworth K, Hollingsworth KG, Thoma C, Jakovljevic D, MacGowan GA, Anstee QM, Taylor R, Day CP, Trenell MI. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J Hepatol 2013; 58: 757-762 [PMID: 23178979 DOI: 10.1016/j.jhep.2012.11.015]
81. Alp H, Karaarslan S, Selver Eklioǧlu B, Atabek ME, Alti{dotless}n H, Baysal T. Association between nonalcoholic fatty liver disease and cardiovascular risk in obese children and adolescents. Can J Cardiol 2013; 29: 1118-1125 [PMID: 23040432. DOI: 10.1016/j.cjca.2012.07.846]
82. Singh GK, Vitola BE, Holland MR, Sekarski T, Patterson BW, Magkos F, Klein S. Alterations in ventricular structure and function in obese adolescents with nonalcoholic fatty liver disease. J Pediatr 2013; 162: 1160-118, 1168. e1 [PMID: 23260104. DOI: 10.1016/j.jpeds.2012.11.024]
83. Sert A, Aypar E, Pirgon O, Yilmaz H, Odabas D, Tolu I. Left ventricular function by echocardiography, tissue Doppler imaging, and carotid intima-media thickness in obese adolescents with nonalcoholic fatty liver disease. Am J Cardiol 2013; 112: 436-443 [PMID: 23642511 DOI: 10.1016/ j.amjcard.2013.03.056]
84. Pacifico L, Di Martino M, De Merulis A, Bezzi M, Osborn JF, Catalano C, Chiesa C. Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease. Hepatology 2013 Jul 11; Epub ahead of print [PMID: 23843206. DOI: 10.1002/hep.26610]
85. Dhingra R, Gona P, Wang TJ, Fox CS, D'Agostino RB, Vasan RS. Serum gamma-glutamyl transferase and risk of heart failure in the community. Arterioscler Thromb Vasc Biol 2010; 30: 1855-1860 [PMID: 20539015 DOI: 10.1161/ATVBAHA. 110.207340]
86. Wannamethee SG, Whincup PH, Shaper AG, Lennon L, Sattar N. Γ-glutamyltransferase, hepatic enzymes, and risk of incident heart failure in older men. Arterioscler Thromb Vasc Biol 2012; 32: 830-835 [PMID: 22223732 DOI: 10.1161/ ATVBAHA.111.240457]
87. Sinner MF, Wang N, Fox CS, Fontes JD, Rienstra M, Magnani JW, Vasan RS, Calderwood AH, Pencina M, Sullivan LM, Ellinor PT, Benjamin EJ. Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation. Am J Cardiol 2013; 111: 219-224 [PMID: 23127690 DOI: 10.1016/j.amjcard.2012.09.021]
88. Lip GY, Tse HF, Lane DA. Atrial fibrillation. Lancet 2012; 379: 648-661 [PMID: 22166900 DOI: 10.1016/S0140-6736]
89. Kleiger RE, Stein PK, Bigger JT. Heart rate variability: measurement and clinical utility. Ann Noninvasive Electrocardiol 2005; 10: 88-101 [PMID: 15649244 DOI: 10.1111/j.1542-474X.2005.10101.x]
90. Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation 1991; 83: 1888-1894 [PMID: 2040041. DOI: 10.1161/01.CIR.83.6.1888]
91. Straus SM, Kors JA, De Bruin ML, van der Hooft CS, Hofman A, Heeringa J, Deckers JW, Kingma JH, Sturkenboom MC, Stricker BH, Witteman JC. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol 2006; 47: 362-367 [PMID: 16412861 DOI: 10.1016/j.jacc.2005.08.067]
92. Okin PM, Devereux RB, Lee ET, Galloway JM, Howard BV. Electrocardiographic repolarization complexity and abnormality predict all-cause and cardiovascular mortality in diabetes: the strong heart study. Diabetes 2004; 53: 434-440 [PMID: 14747295]
93. Liu YC, Hung CS, Wu YW, Lee YC, Lin YH, Lin C, Lo MT, Chan CC, Ma HP, Ho YL, Chen CH. Influence of non-alcoholic fatty liver disease on autonomic changes evaluated by the time domain, frequency domain, and symbolic dynamics of heart rate variability. PLoS One 2013; 8: e61803 [PMID: 23626730. DOI: 10.1371/journal.pone.0061803]
94. Newton JL, Pairman J, Wilton K, Jones DE, Day C. Fatigue and autonomic dysfunction in non-alcoholic fatty liver disease. Clin Auton Res 2009; 19: 319-326 [PMID: 19768633 DOI: 10.1007/s10286-009-0031-4]
95. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994; 90: 844-853 [PMID: 7519131. DOI: 10.1161/01.CIR.90.2.844]
96. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999; 341: 142-147 [PMID: 10403851 DOI: 10.1056/ NEJM199907153410302]
97. Barasch E, Gottdiener JS, Marino Larsen EK, Chaves PH, Newman AB. Cardiovascular morbidity and mortality in community-dwelling elderly individuals with calcification of the fibrous skeleton of the base of the heart and aortosclerosis (The Cardiovascular Health Study). Am J Cardiol 2006; 97: 1281-1286 [PMID: 16635596 DOI: 10.1016/ j.amjcard.2005.11.065]
98. Rossi A, Targher G, Zoppini G, Cicoira M, Bonapace S, Negri C, Stoico V, Faggiano P, Vassanelli C, Bonora E. Aortic and mitral annular calcifications are predictive of all-cause and cardiovascular mortality in patients with type 2 diabetes. Diabetes Care 2012; 35: 1781-1786 [PMID: 22699285 DOI: 10.2337/dc12-0134]
99. Markus MR, Baumeister SE, Stritzke J, Dörr M, Wallaschofski H, Völzke H, Lieb W. Hepatic steatosis is associated with aortic valve sclerosis in the general population: the Study of Health in Pomerania (SHIP). Arterioscler Thromb Vasc Biol 2013; 33: 1690-1695 [PMID: 23685558 DOI: 10.1161/ATVBAHA. 112.300556]
100. Verrijken A, Francque S, Mertens I, Prawitt J, Caron S, Hubens G, Van Marck E, Staels B, Michielsen P, Gaal LV. Prothrombotic factors in histologically proven NAFLD and NASH. Hepatology 2013 May 23; Epub ahead of print [PMID: 23703589. DOI: 10.1002/hep.26510]
101. Simonen M, Männistö V, Leppänen J, Kaminska D, Kärjä V, Venesmaa S, Käkelä P, Kuusisto J, Gylling H, Laakso M, Pihlajamäki J. Desmosterol in human nonalcoholic steatohepatitis. Hepatology 2013; 58: 976-982 [PMID: 23447451 DOI: 10.1002/hep.26342]
102. Musso G, Cassader M, De Michieli F, Rosina F, Orlandi F, Gambino R. Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism. Hepatology 2012; 56: 933-942 [PMID: 22684858. DOI: 10.1002/hep.25739]
103. Musso G, Cassader M, Bo S, De Michieli F, Gambino R. Sterol regulatory element-binding factor 2 (SREBF-2) predicts 7-year NAFLD incidence and severity of liver disease and lipoprotein and glucose dysmetabolism. Diabetes 2013; 62: 1109-1120 [PMID: 23274901 DOI: 10.2337/db12-0858]
104. Sookoian S, Gianotti TF, Rosselli MS, Burgueño AL, Castaño GO, Pirola CJ. Liver transcriptional profile of atherosclerosis-related genes in human nonalcoholic fatty liver disease. Atherosclerosis 2011; 218: 378-385 [PMID: 21664615 DOI: 10.1016/j.atherosclerosis.2011.05.014]
105. Ndumele CE, Nasir K, Conceiçao RD, Carvalho JA, Blumenthal RS, Santos RD. Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler Thromb Vasc Biol 2011; 31: 1927-1932 [PMID: 21546603 DOI: 10.1161/ATVBAHA.111.228262]
106. Papatheodoridis GV, Chrysanthos N, Cholongitas E, Pavlou E, Apergis G, Tiniakos DG, Andrioti E, Theodossiades G, Archimandritis AJ. Thrombotic risk factors and liver histologic lesions in non-alcoholic fatty liver disease. J Hepatol 2009; 51: 931-938 [PMID: 19726097 DOI: 10.1016/ j.jhep.2009.06.023]
107. Assy N, Bekirov I, Mejritsky Y, Solomon L, Szvalb S, Hussein O. Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases. World J Gastroenterol 2005; 11: 5834-5839 [PMID: 16270394]
108. Targher G, Bertolini L, Rodella S, Lippi G, Franchini M, Zoppini G, Muggeo M, Day CP. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) 2008; 16: 1394-1399 [PMID: 18369343. DOI: 10.1038/oby.2008.64]
109. Targher G, Byrne CD. Diagnosis and management of nonalcoholic fatty liver disease and its hemostatic/thrombotic and vascular complications. Semin Thromb Hemost 2013; 39: 214-228 [PMID: 23397556 DOI: 10.1055/s-0033-1334866]
110. Nyrnes A, Njølstad I, Mathiesen EB, Wilsgaard T, Hansen JB, Skjelbakken T, Jørgensen L, Løchen ML. Inflammatory biomarkers as risk factors for future atrial fibrillation. An eleven-year follow-up of 6315 men and women: the Tromsø study. Gend Med 2012; 9: 536-547. e2 [PMID: 23046763 DOI: 10.1016/j.genm.2012.09.001]
111. Liu T, Li G, Li L, Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol 2007; 49: 1642-1648 [PMID: 17433956 DOI: 10.1016/j.jacc.2006.12.042]
112. Lonardo A, Bellentani S, Ratziu V, Loria P. Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient-death of a dogma from analysis of therapeutic studies? Expert Rev Gastroenterol Hepatol 2011; 5: 279-289 [PMID: 21476922. DOI: 10.1586/egh.11.19]
113. Razani B, Chakravarthy MV, Semenkovich CF. Insulin resistance and atherosclerosis. Endocrinol Metab Clin North Am 2008; 37: 603-621, viii [PMID: 18775354 DOI: 10.1016/ j.ecl.2008.05.001]
114. DeFilippis AP, Blaha MJ, Martin SS, Reed RM, Jones SR, Nasir K, Blumenthal RS, Budoff MJ. Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2013; 227: 429-436 [PMID: 23419204. DOI: 10.1016/j.atherosclerosis.2013.01.022]
115. Liu J, Fox CS, Hickson D, Bidulescu A, Carr JJ, Taylor HA. Fatty liver, abdominal visceral fat, and cardiometabolic risk factors: the Jackson Heart Study. Arterioscler Thromb Vasc Biol 2011; 31: 2715-2722 [PMID: 21885852 DOI: 10.1161/ATVBAHA. 111.234062]
116. Pastromas S, Terzi AB, Tousoulis D, Koulouris S. Postprandial lipemia: an under-recognized atherogenic factor in patients with diabetes mellitus. Int J Cardiol 2008; 126: 3-12 [PMID: 17689745 DOI: 10.1016/j.ijcard.2007.04.172]
117. Goldberg IJ, Eckel RH, McPherson R. Triglycerides and heart disease: still a hypothesis? Arterioscler Thromb Vasc Biol 2011; 31: 1716-1725 [PMID: 21527746 DOI: 10.1161/ATVBAHA. 111.226100]
118. Newton JL, Jones DE, Henderson E, Kane L, Wilton K, Burt AD, Day CP. Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut 2008; 57: 807-813 [PMID: 18270241. DOI: 10.1136/gut.2007.139303]
119. Newton JL. Systemic symptoms in non-alcoholic fatty liver disease. Dig Dis 2010; 28: 214-219 [PMID: 20460914 DOI: 10.1159/000282089]
120. Jakovljevic DG, Hallsworth K, Zalewski P, Thoma C, Klawe JJ, Day CP, Newton J, Trenell MI. Resistance exercise improves autonomic regulation at rest and haemodynamic response to exercise in non-alcoholic fatty liver disease. Clin Sci (Lond) 2013; 125: 143-149 [PMID: 23458257 DOI: 10.1042/CS20120684]
121. Ahmed MH, Byrne CD. Obstructive sleep apnea syndrome and fatty liver: association or causal link? World J Gastroenterol 2010; 16: 4243-4252 [PMID: 20818807 DOI: 10.3748/wjg. v16.i34.4243]
122. Musso G, Cassader M, Olivetti C, Rosina F, Carbone G, Gambino R. Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obes Rev 2013; 14: 417-431 [PMID: 23387384 DOI: 10.1111/obr.12020]
123. Kohler M, Stradling JR. Mechanisms of vascular damage in obstructive sleep apnea. Nat Rev Cardiol 2010; 7: 677-685 [PMID: 21079639 DOI: 10.1038/nrcardio.2010.145]
124. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53: 372-384 [PMID: 20494470. DOI: 10.1016/j.jhep.2010.04.008]
125. Loria P, Adinolfi LE, Bellentani S, Bugianesi E, Grieco A, Fargion S, Gasbarrini A, Loguercio C, Lonardo A, Marchesini G, Marra F, Persico M, Prati D, Baroni GS. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis 2010; 42: 272-282 [PMID: 20171943 DOI: 10.1016/ j.dld.2010.01.021]
126. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023 [PMID: 22488764 DOI: 10.1002/hep.25762]
127. Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, Lonardo A. From NAFLD in clinical practice to answers from guidelines. J Hepatol 2013; 59: 859-871 [PMID: 23751754 DOI: 10.1016/j.jhep.2013.05.044]
128. Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol 2012; 56: 255-266 [PMID: 21723839. DOI: 10.1016/j.jhep.2011.06.010]
129. Johnson NA, George J. Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease. Hepatology 2010; 52: 370-381 [PMID: 20578153 DOI: 10.1002/ hep.23711]
130. Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Taylor R, Day CP, Trenell MI. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 2011; 60: 1278-1283 [PMID: 21708823 DOI: 10.1136/gut.2011.242073]
131. Bae JC, Suh S, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Kim SW, Hur KY, Kim JH, Lee MS, Lee MK, Kim KW, Lee WY. Regular exercise is associated with a reduction in the risk of NAFLD and decreased liver enzymes in individuals with NAFLD independent of obesity in Korean adults. PLoS One 2012; 7: e46819 [PMID: 23110056 DOI: 10.1371/journal. pone.0046819]
132. Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012; 57: 157-166 [PMID: 22414768. DOI: 10.1016/j.jhep.2012.02.023]
133. Bacchi E, Negri C, Targher G, Faccioli N, Lanza M, Zoppini G, Zanolin E, Schena F, Bonora E, Moghetti P. Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial). Hepatology 2013; 58: 1287-1295 [PMID: 23504926 DOI: 10.1002/hep.26393]
134. Bhupathiraju SN, Tucker KL. Coronary heart disease prevention: nutrients, foods, and dietary patterns. Clin Chim Acta 2011; 412: 1493-1514 [PMID: 21575619 DOI: 10.1016/ j.cca.2011.04.038]
135. Kardassis D, Bech-Hanssen O, Schönander M, Sjöström L, Karason K. The influence of body composition, fat distribution, and sustained weight loss on left ventricular mass and geometry in obesity. Obesity (Silver Spring) 2012; 20: 605-611 [PMID: 21566562 DOI: 10.1038/oby.2011.101]
136. Frohlich J, Al-Sarraf A. Cardiovascular risk and atherosclerosis prevention. Cardiovasc Pathol 2013; 22: 16-18 [PMID: 22502868. DOI: 10.1016/j.carpath.2012.03.001]
137. Mathur N, Pedersen BK. Exercise as a mean to control lowgrade systemic inflammation. Mediators Inflamm 2008; 2008: 109502 [PMID: 19148295 DOI: 10.1155/2008/109502]
138. Vepsäläinen T, Soinio M, Marniemi J, Lehto S, Juutilainen A, Laakso M, Rönnemaa T. Physical activity, highsensitivity C-reactive protein, and total and cardiovascular disease mortality in type 2 diabetes. Diabetes Care 2011; 34: 1492-1496 [PMID: 21602429 DOI: 10.2337/dc11-0469]
139. Rabl C, Campos GM. The impact of bariatric surgery on nonalcoholic steatohepatitis. Semin Liver Dis 2012; 32: 80-91 [PMID: 22418890 DOI: 10.1055/s-0032-1306428]
140. Carulli L, Maurantonio M, Hebbard L, Baldelli E, Loria P, George J. Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLD. Curr Pharm Des 2013; 19: 5280-5296 [PMID: 23394096 DOI: 10.2174/13816128 11319290009]
141. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Antidiabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 881-91; quiz 892 [PMID: 23381014 DOI: 10.1038/ ajg.2013.5]
142. Zhang H, Gao C, Fang L, Zhao HC, Yao SK. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. Scand J Gastroenterol 2013; 48: 78-87 [PMID: 23137049 DOI: 10.3109/00365521.2012.719926]
143. Chen HP, Shieh JJ, Chang CC, Chen TT, Lin JT, Wu MS, Lin JH, Wu CY. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 2013; 62: 606-615 [PMID: 22773548]
144. Ratziu V, Caldwell S, Neuschwander-Tetri BA. Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues. Hepatology 2010; 52: 2206-2215 [PMID: 21105109 DOI: 10.1002/hep.24042]
145. Rakoski MO, Singal AG, Rogers MA, Conjeevaram H. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2010; 32: 1211-1221 [PMID: 20955440 DOI: 10.1111/ j.1365-2036.2010.04467.x]
146. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012; 55: 885-904 [PMID: 22278337. DOI: 10.1007/s00125-011-2446-4]
147. Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, Borg B, Loomba R, Liang TJ, Premkumar A, Hoofnagle JH. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007; 46: 424-429 [PMID: 17559148 DOI: 10.1002/hep.21661]
148. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298: 1180-1188 [PMID: 17848652 DOI: 10.1001/jama]
149. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012; 55: 1953-1962 [PMID: 22460763 DOI: 10.1007/s00125-012-2538-9]
150. Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience. N Engl J Med 2013; 369: 1285-1287 [PMID: 23992603 DOI: 10.1056/NEJMp1309610]
151. Wajcberg E, Tavaria A. Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother 2009; 10: 135-142 [PMID: 19236187. DOI: 10.1517/14656560802611832]
152. Trevaskis JL, Griffin PS, Wittmer C, Neuschwander-Tetri BA, Brunt EM, Dolman CS, Erickson MR, Napora J, Parkes DG, Roth JD. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol 2012; 302: G762-G772 [PMID: 22268099 DOI: 10.1152/ajpgi.00476.2011]
153. Zhang L, Yang M, Ren H, Hu H, Boden G, Li L, Yang G. GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK. Liver Int 2013; 33: 794-804 [PMID: 23432843 DOI: 10.1111/liv.12120]
154. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24: 275-286 [PMID: 18053320]
155. Cuthbertson DJ, Irwin A, Gardner CJ, Daousi C, Purewal T, Furlong N, Goenka N, Thomas EL, Adams VL, Pushpakom SP, Pirmohamed M, Kemp GJ. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS One 2012; 7: e50117 [PMID: 23236362 DOI: 10.1371/journal.pone.0050117]
156. Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity (Silver Spring) 2011; 19: 2310-2315 [PMID: 21660077 DOI: 10.1038/oby.2011.152]
157. Mundil D, Cameron-Vendrig A, Husain M. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diab Vasc Dis Res 2012; 9: 95-108 [PMID: 22496442 DOI: 10.1177/1479164112441526]
158. Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, Pagourelias ED, Theocharidou E, Karagiannis A, Mikhailidis DP. Safety and efficacy of longterm statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376: 1916-1922 [PMID: 21109302 DOI: 10.1016/S0140-6736(10)61272-x]
159. Tikkanen MJ, Fayyad R, Faergeman O, Olsson AG, Wun CC, Laskey R, Kastelein JJ, Holme I, Pedersen TR. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-tomoderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013; 168: 3846-3852 [PMID: 24001698 DOI: 10.1016/j.ijcard.2013.06.024]
160. Lonardo A, Loria P. Potential for statins in the chemoprevention and management of hepatocellular carcinoma. J Gastroenterol Hepatol 2012; 27: 1654-1664 [PMID: 22849701 DOI: 10.1111/j.1440-1746.2012.07232.x]
161. Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag 2012; 8: 415-427 [PMID: 22910633 DOI: 10.2147/VHRM. S33664]
162. Van Rooyen DM, Gan LT, Yeh MM, Haigh WG, Larter CZ, Ioannou G, Teoh NC, Farrell GC. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. J Hepatol 2013; 59: 144-152 [PMID: 23500152 DOI: 10.1016/j.jhep.2013.02.024]
163. Park H, Shima T, Yamaguchi K, Mitsuyoshi H, Minami M, Yasui K, Itoh Y, Yoshikawa T, Fukui M, Hasegawa G, Nakamura N, Ohta M, Obayashi H, Okanoue T. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 101-107 [PMID: 20658156. DOI: 10.1007/s00535-010-0291-8]
164. Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012; 56: 944-951 [PMID: 22023985 DOI: 10.1016/ j.jhep.2011.08.018]
165. Marik PE, Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol 2009; 32: 365-372 [PMID: 19609891 DOI: 10.1002/ clc.20604]
166. Roncaglioni MC, Tombesi M, Avanzini F, Barlera S, Caimi V, Longoni P, Marzona I, Milani V, Silletta MG, Tognoni G, Marchioli R. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med 2013; 368: 1800-1808 [PMID: 23656645 DOI: 10.1056/NEJMoa1205409]
167. Hsueh WA, Wyne K. Renin-Angiotensin-aldosterone system in diabetes and hypertension. J Clin Hypertens (Greenwich) 2011; 13: 224-237 [PMID: 21466617 DOI: 10.1111/ j.1751-7176.2011.00449.x]
168. Schuppan D, Gorrell MD, Klein T, Mark M, Afdhal NH. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int 2010; 30: 795-808 [PMID: 20624207 DOI: 10.1111/j.1478-3231.2010.02264.x]
169. Kudo H, Yata Y, Takahara T, Kawai K, Nakayama Y, Kanayama M, Oya T, Morita S, Sasahara M, Mann DA, Sugiyama T. Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue. Liver Int 2009; 29: 988-996 [PMID: 19386026. DOI: 10.1111/j.1478-3231.2009.02006.x]
170. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, Hasegawa T, Tokusashi Y, Miyokawa N, Nakamura K. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004; 40: 1222-1225 [PMID: 15382153 DOI: 10.1002/ hep.20420]
171. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs 2004; 64: 2537-2565 [PMID: 15516153]
172. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL, Coca A, Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD, Bauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germano G, Gielen S, Haller H, Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH, Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Rydén L, Sirenko Y, Stanton A, Struijker-Boudier H, Tsioufis C, van de Borne P, Vlachopoulos C, Volpe M, Wood DA. ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-2219 [PMID: 23771844 DOI: 10.1093/ eurheartj/eht151]
173. Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, Haussler MR, Mangelsdorf DJ. Vitamin D receptor as an intestinal bile acid sensor. Science 2002; 296: 1313-1316 [PMID: 12016314]
174. Targher G, Pichiri I, Lippi G. Vitamin D, thrombosis, and hemostasis: more than skin deep. Semin Thromb Hemost 2012; 38: 114-124 [PMID: 22314609 DOI: 10.1055/s-0031-1300957]
175. Eliades M, Spyrou E, Agrawal N, Lazo M, Brancati FL, Potter JJ, Koteish AA, Clark JM, Guallar E, Hernaez R. Metaanalysis: vitamin D and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013; 38: 246-254 [PMID: 23786213 DOI: 10.1111/apt.12377]
176. Targher G, Bertolini L, Scala L, Cigolini M, Zenari L, Falezza G, Arcaro G. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2007; 17: 517-524 [PMID: 16928437 DOI: 10.1016/ j.numecd.2006.04.002]
177. Targher G, Scorletti E, Mantovani A, Byrne CD. Nonalcoholic fatty liver disease and reduced serum vitamin D(3) levels. Metab Syndr Relat Disord 2013; 11: 217-228 [PMID: 23745619. DOI: 10.1089/met.2013.0044]
178. Lee JH, O'Keefe JH, Bell D, Hensrud DD, Holick MF. Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol 2008; 52: 1949-1956 [PMID: 19055985 DOI: 10.1016/j.jacc.2008.08.050]
179. Lutsey PL, Michos ED. Vitamin D, calcium, and atherosclerotic risk: evidence from serum levels and supplementation studies. Curr Atheroscler Rep 2013; 15: 293 [PMID: 23232985 DOI: 10.1007/s11883-012-0293-5]
180. Fall T, Shiue I, Bergeå af Geijerstam P, Sundström J, Ärnlöv J, Larsson A, Melhus H, Lind L, Ingelsson E. Relations of circulating vitamin D concentrations with left ventricular geometry and function. Eur J Heart Fail 2012; 14: 985-991 [PMID: 22723659 DOI: 10.1093/eurjhf/hfs091]